Regulatory News:
Commenting on the first nine months of 2013, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen, said: “Over the first 9 months of the year, Somatuline® and Dysport® have continued to post solid growths of respectively 12.0%1 and 6.8%1.
Help employers find you! Check out all the jobs and post your resume.
